Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
Open Access
- 1 December 2021
- journal article
- case report
- Published by Springer Nature in npj Precision Oncology
- Vol. 5 (1) , 1-7
Abstract
Acquired resistance to molecular targeted therapy is a significant challenge of the precision medicine era. The ability to understand these mechanisms of resistance may improve patient selection and allow for the development of rationally designed next-line or combination treatment strategies and improved patient outcomes. AKT is a critical effector of the phosphoinositide 3-kinase signaling cascade, one of the most commonly activated pathways in human cancer. Deregulation of signaling pathways, such as RAF/MEK/ERK are previously described mechanisms of resistance to AKT/PI3K inhibitors. Mutations in the mTOR gene, however, are exceedingly rare. We present a case of acquired mTOR resistance, following targeted AKT inhibition, and subsequent response to mTOR1/2 inhibitor in a patient with metastatic endometrial cancer, the first documented response to ATP-competitive mTOR inhibition in this setting. This case supports mTOR mutation as a mechanism of resistance, and underscores the importance of tumor molecular profiling, exemplifying precision medicine in action.Keywords
This publication has 47 references indexed in Scilit:
- Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) DomainPLOS ONE, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Starting with the ABCs: Akt in Breast CancerMolecular Cancer Therapeutics, 2011
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitroCell Cycle, 2009
- The life of a cell: apoptosis regulation by the PI3K/PKB pathwayBiochemical Journal, 2008
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promisesCurrent Opinion in Pharmacology, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- TOR Signaling in Growth and MetabolismCell, 2006
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002